Inclusion of non-inferiority analysis in superiority-based clinical trials with single-arm, two-stage Simon's design by Sampayo-Cordero, Miguel et al.
Contemporary Clinical Trials Communications 20 (2020) 100678
Available online 28 November 2020
2451-8654/© 2020 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Inclusion of non-inferiority analysis in superiority-based clinical trials with 
single-arm, two-stage Simon’s design 
Miguel Sampayo-Cordero a,l,*, Bernat Miguel-Huguet b, José Pérez-García a,c, David Páez a,d, 
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A B S T R A C T   
Introduction: Non-inferiority (NI) analysis is not usually considered in the early phases of clinical development. In 
some negative phase II trials, a post-hoc NI analysis justified additional phase III trials that were successful. 
However, the risk of false positive achievements was not controlled in these early phase analyses. We propose to 
preplan NI analyses in superiority-based Simon’s two-stage designs to control type I and II error rates. 
Methods: Simulations have been proposed to assess the control of type I and II errors rates with this method. A 
total of 12,768 two-stage Simon’s design trials were constructed based on different assumptions of rejection 
response probability, desired response probability, type I and II errors, and NI margins. P-value and type II error 
were calculated with stochastic ordering using Uniformly Minimum Variance Unbiased Estimator. Type I and II 
errors were simulated using the Monte Carlo method. The agreement between calculated and simulated values 
was analyzed with Bland-Altman plots. 
Results: We observed the same level of agreement between calculated and simulated type I and II errors from both 
two-stage Simon’s superiority designs and designs in which NI analysis was allowed. Different examples has been 
proposed to explain the utility of this method. 
Conclusion: Inclusion of NI analysis in superiority-based single-arm clinical trials may be useful for weighing 
additional factors such as safety, pharmacokinetics, pharmacodynamic, and biomarker data while assessing early 
efficacy. Implementation of this strategy can be achieved through simple adaptations to existing designs for one- 
arm phase II clinical trials.   
1. Introduction 
A single-arm phase II trial is the proof-of-concept stage in drug 
development, and focuses on the evaluation of new therapeutic 
hypothesis and strategies in a clinical setting [1,2]. Phase II studies in 
oncology are often multistage trials. Two-stage designs are becoming 
increasingly more common, allowing for early trial termination in cases 
with low response rates (RRs) towards avoiding wasting time resources 
on ineffective treatments. These trials aim to determine whether the new 
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regimen is superior to a pre-specified RR (often 5%) or experience with 
the standard of care, whereas the alternative hypothesis is that RR is 
somewhat higher, say 20% [3,4]. 
Nevertheless, the non-inferiority (NI) question might also be relevant 
in the phase II setting [5]. A typical scenario is one in which an exper-
imental treatment is potentially less toxic, less costly, easier to admin-
ister or with novel biological pathways than a conventional treatment, 
but these do not represent a reduction of efficacy or in percentage of 
patient with clinical benefit [6]. 
In accordance with the European Medicines Agency guidelines [7], 
in any superiority trial where NI may be an acceptable outcome, it is 
prudent to specify a NI margin in the protocol to avoid serious diffi-
culties that can arise from later designation. Specification of a margin 
after viewing the results can produce an increase in the alpha error rate 
[8]. In 2016, the Food and Drug Administration published guidelines to 
establish effectiveness in NI trials. The statistical issues associated with 
NI studies, and procedures used to determine the NIM, have been 
extensively described [6]. 
Among all available multistage designs, the most popular is a two- 
stage design with a futility stopping point based on Simon’s minimax 
or optimal criterion [9]. The simplicity of Simon’s design may account 
for its popularity. However, the inference procedures used in two-stage 
designs are often not corrected to account for these designs’ adaptive 
nature [10]. For point estimation, previous authors have developed a 
method to calculate the Uniformly Minimum Variance Unbiased Esti-
mator (UMVUE) for Simon’s designs and to achieve optimal results. 
What is more, p-values and type II errors can be calculated with sto-
chastic ordering of the UMVUE [9,11]. These methods can be used when 
the realized sample size at the stopping stage is different from that 
specified in the initial design, and this property makes them very useful 
for designing and analyzing two-stage phase II trials [9]. 
The aim of the present study is to assess the validity of the UMVUE- 
based calculation method planning two-stage Simon’s design phase II 
trials with a superiority analysis, where NI analysis is also allowed. 
2. Methods 
2.1. NI analysis 
In a NI analysis, the goal of the study is to show that the effect of the 
test drug (p) is not inferior to the effect of the active control (p0) by a 
specified amount, called NIM. The null and alternative hypotheses 
should be defined as follows [6]:  
H0: p0 – p ≥ NIM (p is inferior to the control (p0) by NIM or more);       (1)  
Ha: p0 – p < NIM (p is inferior to the control (p0) by less than NIM).      (2) 
A challenging point in NI analysis is to distinguish an effective 
treatment from a less effective or ineffective treatment. The presence of 
assay sensitivity in a NI trial should be stated from: i) historical evidence 
of sensitivity to drug effects based on well controlled trials and a robust 
statistical and clinical judgment (e.g. A treatment cannot be used as a 
control arm if the superiority against placebo was inconclusive in his-
torical studies); and ii) appropriate conduct of the trial that adheres 
closely to the design of the trials used to determine that historical evi-
dence of sensitivity to drug effects exists [12]. The margin chosen for a 
NI trial should be defined prior to study initiation, taking into these 
historical evidences. Although the NI margin used in a trial can be no 
larger than the entire assumed effect of the active control against pla-
cebo (M1), it is generally desirable to choose a lower margin (M2) that 
reflects the largest loss of effect that would be clinically acceptable [6]. 
Showing NI to M1 provides assurance that the test drug had an effect 
greater than zero, but, in many cases, that is not sufficient to conclude 
that the test drug had a clinically acceptable effect [6]. In a fixed margin 
approach, the NIM could be considered as the risk ratio or risk differ-
ence, reflective of the average effect of the active control over placebo in 
previous studies [(pcontrol/pplacebo) > 1 or (pcontrol - pplacebo) > 0], for 
example:  
Relative risk = 2.64, 95% confidence interval (CI): (1.72 to 3.56).           (3)  
Risk difference = 0.15, 95% CI: (0.07 to 0.22).                                    (4) 
We selected the 95% CI lower bound (1.72 or 0.07) and adjusted to 
retain at least 50% of the historical effect of active control versus pla-
cebo arm ([1.72^(1-0.5) = 1.31] or [0.07*(1-0.5) = 0.035]) [6]. 
Accordingly, the calculated NIM describes a ratio or a difference 
reflecting the largest loss of effect in control group RR (p0) that would be 
clinically acceptable. Therefore, the null and alternative hypothesis of 
NI analysis can be defined as follows and depending on p0/NIM:  
H0: p ≤ (p0 / NIMas ratio) or H0: p ≤ (p0 - NIMas difference);                     (5)  
H1: p > (p0 / NIMas ratio) or H1: p > (p0 - NIMas difference);                     (6) 
Risk ratio is preferred because it is less affected than risk differences 
by variability in the event rates in the placebo group [6]. 
2.2. Include a NI analyses in a superiority based single-arm design 
In a superiority analysis design with tumor response as the primary 
endpoint, analyze firstly a NI hypothesis does not inflate the type I error 
rate when NI analysis and NIM are properly pre-specified [7]. Addi-
tionally, the final number of responders needed to achieve the NI 
objective will always equal or lower than the prespecified superiority 
efficacy boundary (a) [7].Therefore, we assumed the same number of 
patients as in superiority analysis (n); and ani (number of responding 
patients in NI analysis) is chosen as the lowest integer satisfying the type 
I error rate in NI analysis (αni) ≤ α:  
B(ani|n, p0 / NIM) ≥ 1- α.                                                                 (7) 
The power should be calculated:  
1 - βni = B(ani − 1|n, p0/NIM); where ani ≤ a; 1 - β ≤ 1 - βni.                 (8) 
Accordingly, the study will achieve a positive finding when “p” is 
equal or higher than “p0/NIM” and significance level evaluated by 
binomial test in NI analysis is ≤ α. As the NI analysis has the same ex-
pected accrual and lower or equal number of responders needed to 
declare significance than superiority analysis (ani ≤ a), power always 
Abbrevations 
α The planned level of type I error 
1 ‒ β The planned level of power 
a The prespecified superiority efficacy boundary 
ani The prespecified no-inferiority efficacy boundary 
CI Confidence interval 
FDA Food and drug administration 
M1 The assumed effect of the active control against placebo 
M2 The largest loss of effect that would be clinically 
acceptable 
n The number of patients the end of the trial 
n1 The number of patients at the interim analysis 
NI Non-inferiority 
NIM Non-inferiority margin 
p The effect of the test drug 
p0 The effect of the drug under the null hypothesis (or the 
effect of the active control therapy) 
p1 The effect of the drug under the alternative hypothesis 
RR Response rates 
UMVUE Uniformly Minimum Variance Unbiased Estimator  
M. Sampayo-Cordero et al.                                                                                                                                                                                                                   
Contemporary Clinical Trials Communications 20 (2020) 100678
3
will be equal or greater in NI than superiority criteria. Thus, this design 
can assess superiority and NI criteria with the same sample size, type I 
and type II error rates used in the superiority strategy (as outlined in the 
Supplementary Methods) [7]. 
Additionally, in a single-arm two-stage Simon’s design, UMVUE- 
based calculation of p-value is still valid when the realized sample size 
and number of responders to achieve a positive finding are different at 
the stopping stage from that specified in the design (as outlined in the 
Supplementary Methods) [9]. Thus, include a NI strategy in a superiority 
based single-arm trial may be implemented in Phase II Simon’s designs. 
A numerical example has been proposed in Results section. 
2.3. Simulations 
A total of 12,768 two-stage, single-arm designs were computed based 
on different assumptions of p0, p1, α1, 1 - β. The package “Clinfun” 
(function “ph2simon”) from R software [13] was used for computing 
these designs [14]. 
The NIMs selected to formulate the rejection proportion ranged be-
tween 1 and 1.45 in 0.05 increments [8]. P-values and type II errors in 
every design were calculated with stochastic ordering of UMVUE [9]. A 
user-defined function in the R software was used for calculating these 
P-values and type II errors. Alpha and beta errors were simulated with 
the Monte Carlo method. Number of random samples generated were 
based on the need to attain 95% confidence, so that simulated values of 
alpha and beta errors were within 0.5% and 1% of the true values, 
respectively [15]. Agreement between calculated and simulated values 
were analyzed with Bland-Altman plots (as outlined in the Supplemen-
tary Methods) [16,17]. The R code detailing this process and illustrating 
the simulations can be found in the Supplemental Files 1 and 2. The 
datasets generated in these analyses can be found in supplemental 
datasets 0, 1, and 2. A summary detailing the information reported in 
these supplementary files can be found in the SupplementaryDataSum-
mary document. 
3. Results 
3.1. Agreement between simulated and calculated statistical errors 
The results showed a proportional bias between calculated p-values 
and simulated alpha levels. Higher levels of type I error related to 
greater absolute differences between the calculated p-values and simu-
lated alpha errors. This is not surprising considering that high statistical 
error is likely reflective of small sample size and high imprecision. 
Moreover, we observed that the lower boundary of the 95% CI was 
crossed by more than 2.5% of the differences. This finding suggests that 
calculated p-values tended to be slightly lower than the simulated alpha 
values (Fig. 1). 
However, it is important to consider that these two biases are com-
mon in superiority designs with (NIM>1) and without (NIM = 1) NI 
analyses. Additionally, the percentage of values crossing the 95% CI 
boundary is equivalent in both designs (Fig. 1). Comparison of type II 
errors also reflected that calculated type II errors tended to be slightly 
lower than the simulated type II errors. However, superiority design 
with and without NI strategy displayed equivalent results with about 
95% limits of agreement (Fig. 2). 
In the superiority scenarios (NIM = 1), we observed that the cloud of 
points was grouped in values of 0.01, 0.05, and 0.1 for the p-value, and 
0.1 and 0.2 for the type II error. This is consistent with the pre-specified 
design constrains. However, we did not observe this behavior in sce-
narios where NIM >1, because the designs’ sample sizes were pre- 
specified for superiority analysis. So, type I and II errors that fulfilled 
design constraints for different values of NIM showed higher variability. 
Moreover, there were seven times more scenarios in NIM >1 analysis 
than in superiority analysis (NIM = 1). 
The maximum differences between calculated p-values and type I 
errors were 0.0015, 0.002, and 0.004 for 0.01, 0.05 and 0.1 type I errors, 
respectively (Fig. 1). Therefore, in a study with a 0.01 significance level, 
the maximum simulated type I error ranged from 0.0085 to 0.0115. 
Studies with a 0.05 significance level had maximum simulated type I 
errors ranging from 0.048 to 0.052. Finally, studies with 0.1 significance 
levels had maximum simulated type I errors that ranged from 0.096 to 
0.104 (Fig. 1). 
Regarding beta errors, the maximum bias in designs with 0.1 and 0.2 
type II errors was 0.005, respectively. Therefore, calculated type II er-
rors ranged from 0.195 to 0.205 and from 0.095 to 0.105 for designs 
with 80% and 90% of simulated power, respectively (Fig. 2). These re-
sults suggest that differences between calculated and simulated scores 
are not relevant. 
Collectively, our findings implied that the minimum and maximum 
differences for calculated and simulated values were equivalent in su-
periority (NIM = 1) and NI (NIM > 1) scenarios (Figs. 1 and 2). Addi-
tionally, results suggest that the agreement between calculated and 
simulated statistical errors decrease the greater the error tolerated in the 
statistical design and the calculated statistical errors tend to be lower 
than simulated ones. Therefore, it would not be recommended to plan 
single-arm designs with error constraints more relaxed than usually 
accepted levels (alpha and beta errors equal or lower than 0.2) [18]. 
Absolute differences have been plotted against average of calculated 
and simulated scores. The type I errors values considered were 0.1, 0.05 
Fig. 1. Agreement between calculated p-value and simulated alpha errors in Simon’s two-stage clinical designs.  
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and 0.01, and type II errors values were 0.2 and 0.1. The NIMs selected 
to formulate the rejection proportion (p0/NIM) were (1, 1.15, 1.2, 1.25, 
1.30, 1.35, 1.4, and 1.45). A maximum of 2.5% deviation defined the 
95% limits of agreement. 
Absolute differences have been plotted against average of calculated 
and simulated scores. The type I values considered were 0.1, 0.05 and 
0.01, and type II errors were 0.2 and 0.1. The NIMs selected to formulate 
the rejection proportion (p0/NIM) were (1, 1.15, 1.2, 1.25, 1.30, 1.35, 
1.4 and 1.45). A maximum of 2.5% deviation defined the 95% limits of 
agreement. 
3.2. Numerical example 
We suggest to use a single-arm trial designed to assess a new inves-
tigational therapy combined with an approved drug which represents 
the standard of care [19], or a dose modification of standard of care 
aiming to reduce the probability of related adverse events and improve 
quality of life [20,21]. The safety profile improvement of the standard of 
care will only be acceptable if it is accompanied by a NI result evaluating 
the treatment activity. So, it makes sense to propose a NI contrast for the 
evaluation of early efficacy. In addition, the reduction of toxicity could 
increase adherence to treatment, so the analysis of efficacy in terms of 
superiority should be also considered. This strategy allows us to better 
weigh the risk-benefit ratio of this intervention compared with the 
unique analysis of the safety profile. Our proposal explains how to 
pre-plan this study design to control type I error and avoid the post-hoc 
data review [6]. 
We designed a proof-of-concept study to evaluate if the new inves-
tigational therapy is promising, with less than 30 patients recruited. The 
sequence of the analysis at the end of study firstly assessed the safety 
profile, then the NI efficacy objectives, and finally, the superiority effi-
cacy objective. In accordance with fixed sequence method, the NI and 
superiority analyses only could achieve a positive finding if previous 
assessment met the requirement for statistical significance [22]:  
1) Firstly, we assumed that the safety objective will be achieved at the 
end of the study. On the contrary, if the safety objective had not been 
reached, the efficacy analyzes would not make sense. 
2) Secondly, we planned the statistical design for early efficacy objec-
tive based on two-stage Simon’s design for superiority analyses. We 
planned a 35% historical response rate in standard of care. This 
response rate could range between 30% and 40% in accordance with 
the baseline patients’ characteristics (e.g.: prior therapies received, 
or prior lines of therapy) [24]. 
Thus, rejecting a 20% rate of responders would be a conservative 
approach to assess this therapy (null hypothesis). Moreover, we planned 
to detect an improvement greater than or equal to 45% (which repre-
sented the alternative hypothesis). We proposed an optimal two-stage 
Simon’s design with the same error constraints accepted for the safety 
objective (α = 0.1 and 1 ‒ β = 0.9). For the design parameters:  
(p0, p1, α*, 1 ‒ β*) = (0.20, 0.45, 0.1, 0.9)                                          (9) 
The optimal design was given by:  
(a1 / n1, a / n) = (4 / 14, 8 / 25)                                                       (10) 
where a1, n1, a, and n are the number of responders needed to move to 
the second stage, the number of accrued patients at first stage, the 
number of responders to achieve a positive result at final analysis, and 
the total number of patients recruited, respectively. Calculations were 
implemented in the R “Clinfun” library (function “ph2simon (0.20, 0.45, 
0.1, 0.1)”) [14].  
3) Thirdly, we calculated the number of responders who were needed to 
achieve a significant result at final analysis based on the NI hy-
pothesis. We assumed a NIM of 1.2. The number of patients recruited 
in each stage and interim boundaries (a1, n1, and n) were the same 
than previous superiority design. However, the number of re-
sponders to achieve a positive result in the final analysis were 
reduced:  
(a1 / n1, a / n) = (4/ 14, 7 / 25)                                                       (12) 
The calculation of p-value and 95% confidence intervals were 
implemented in the R “clinfun” or “OneArmPhaseTwoStudy” library 
[11,28]. 
In addition, three potential scenarios of analyses describe why our 
proposal is more informative than the usual alternatives, as follows:  
• Scenario 1: 
At the end of recruitment, a common issue is that clinical trials 
passed partially the pre-designed number of recruited patients. In 
accordance, our study achieved the interim objective to continue to the 
second stage (with at least 4 responders) and passed the target sample 
Fig. 2. Agreement between calculated and simulated type II error in Simon’s two-stage clinical designs.  
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size of two patients (N = 27) at final analysis. The total number of re-
sponders observed at the end of study was 7 (x = 7). However, according 
to the expected sample size, in the first 25 recruited patients only 6 
responses were observed. Analyzing final data with the UMVUE based 
method allowed to analyze all the patients recruited in the study and 
account the adaptive nature of the study due to the interim futility 
analysis [9,27]. The results based on the UMVUE method estimated a 
32.2% rate of responders. The p-values for the NI and superiority 
analysis were 0.097 (<0.1 significant criteria achieved) and 0.194 (>0.1 
non-significant), respectively. These calculations could be performed in 
open-access statistical libraries (packages “clinfun” or “OneArmPha-
seTwoStudy”, R statistical software) [11,28]: 
Package “clinfun”:  
NI analysis: twostage.inference(x, (a1-1), n1, n, p0/NIM)                      (13)  
twostage.inference(7, 3, 14, 27, 0.2/1.2)                                             (14)  
Superiority analysis: twostage.inference(x, (a1-1), n1, n, p0)                 (15)  
twostage.inference(7, 3, 14, 27, 0.2)                                                  (16) 
Package “OneArmPhaseTwoStudy”:  
NI analysis: get_p_KC(x, (a1-1), n1, n, p0/NIM)                                 (17)  
get_p_KC(7, 3, 14, 27, 0.2/1.2)                                                        (18)  
Superiority analysis: get_p_KC(x, (a1-1), n1, n, p0) (19)                               
get_p_KC(7, 3, 14, 27, 0.2) (20)                                                               
Alternatively, we could analyze results based on the pre-designed 
sample size boundaries. We considered the first 25 patients with only 
6 responders (<7 responders, so the result was non-significant). More-
over we could conduct the analysis based on maximum-likelihood 
method without including the interim decision in the analysis [9]. 
This method only considers the total number of responders (x = 7) and 
the total number of patients recruited (n = 27) (function “binom.test”, 
package “stats”, R statistical software). We observed that the maximum 
likelihood method underestimated the rate of responders (25.9% <
32.3%) and did not declare significant differences neither in NI (p-value 
= 0.151) nor superiority analyses (p-value = 0.287). As example in R 
code:  
NI analysis: binom.test(x = 7, n = 27, p = 0.2/1.2, alternative = ’greater’) (21)  
Superiority analysis: binom.test(x = 7, n = 27, p = 0.2, alternative = ’greater’) 
(22) 
However, a significant reduction in the rate of clinically relevant 
adverse events with a 32.2% response rate was a promising result to 
design a randomized trial. This result probably would have led to the 
decision to develop the randomized clinical trial even if the efficacy NI 
analysis was not formally considered. Whenever efficacy is ranked with 
safety, quality of life, cost or any other endpoints, efficacy is always 
evaluated in terms of NI among standard of care [25,29–31]. Never-
theless, it was not formally defined and this post-hoc analyses usually 
increase type I error [6].  
• Scenario 2: 
We would like to propose a scenario whose patients’ recruitment is 
discontinued prior to reach the pre-designed sample size. The study 
started the stage II, but it is finally discontinued with 6 responders and a 
total of 20 patients recruited. Reasons for the study discontinuation were 
not due to safety or efficacy results but to external issues (e.g. a logistic 
problem or a global pandemic) [32]. If we analyze these data based on 
the pre-designed sample size boundaries, we cannot conclude if the 
experimental therapy is promising or not. The number of responders was 
lower than efficacy boundary (≥7 responders), but we cannot reject that 
the boundary will be achieved with a higher number of patients 
recruited. However, if we based the test in the UMVUE method, the 
analysis could be conducted with a different number of patients than 
expected in the sample size [9]. Results based on the UMVUE method 
estimated a 32.9% rate of responders. The p-values for the NI and su-
periority analysis were 0.085 (<0.1 significant criteria achieved) and 
0.167 (>0.1 non-significant), respectively. As example:  
NI analysis: twostage.inference(x, (a1-1), n1, n, p0/NIM)                      (23)  
twostage.inference(6, 3, 14, 20, 0.2/1.2)                                             (24)  
Superiority analysis: twostage.inference(x, (a1-1), n1, n, p0)                 (25)  
twostage.inference(6, 3, 14, 20, 0.2)                                                  (26) 
Alternatively, the maximum likelihood method underestimated the 
rate of responders (30% < 32.9%) and did not declare neither significant 
differences in NI (p-value = 0.102) nor superiority analyses (p-value =
0.199). As example:  
NI analysis: binom.test(x = 6, n = 20, p = 0.2/1.2, alternative = ’greater’) (19)  
Superiority analysis: binom.test(x = 6, n = 20, p = 0.2, alternative = ’greater’) 
(20)                                                                                                     
Moreover, regarding the scenario previously reported, a significant 
reduction in the rate of adverse events with a 32.9% response rate 
represented a promising result to design a future randomized trial.  
• Scenario 3: 
It could be argued that designing a clinical trial with a NI analysis is 
unnecessary because a more conservative null hypothesis (16.7%) could 
be assumed, and the same result should be obtained. However, consid-
ering this alternative, the superiority objective could not be assessed, 
such as during a dose-finding phase I trial [33]. In this context, the study 
design of dose escalation trials usually includes patients who are allo-
cated in different cohorts and have received different dose levels in 
order to identify the maximum tolerate dose (MTD). It is a common 
practice to expand the number of patients recruited in the MTD cohort to 
explore activity and extend the evaluation of safety results. The inclu-
sion of a NI hypothesis in the superiority-based analysis of this extended 
MTD cohort will help to rank the activity data with the other endpoints. 
In accordance, we planned a single-stage, single-arm A’hern design 
[23]. We accepted the same constraints which were reported in the 
previous examples, except for type II error (20%):  
(p0, p1, α, 1 ‒ β, NIM) = (0.20, 0.45, 0.1, 0.2, 1.2) (21)                              
Among 19 patients recruited, we will achieve a positive finding in the 
NI and superiority analyses with 6 (31.5%) and 7 responders (36.8%), 
respectively [23]. In addition to evaluate the clinical pharmacokinetic 
profile of the drug, a phase I study offers the opportunity to test the 
prespecified pharmacodynamic and biomarker hypotheses that were 
obtained in previous pre-clinical studies [34,35]. The aim of these phase 
I studies is to enrich the data obtained in early setting, that in turn will 
allow the study design improvement of further randomized trials 
[35–37]. In accordance with our example, if data suggest both a good 
tolerability with a positive result in the NI analysis, a well-characterized 
pharmacokinetic profile, and a novel target in molecular pathway, the 
randomized trial could be designed combining experimental therapy 
with previous standard of care. Alternatively, the experimental therapy 
will be evaluated as monotherapy in further randomized clinical trials if 
an equivalent toxic profile compared with previous example is obtained, 
with a positive result in superiority analysis, and a similar molecular 
target respect to standard of care. Finally, a vey toxic treatment with a 
higher efficacy than standard of care, or a non-toxic treatment without a 
clinically meaningfully activity will not be tested in a new randomized 
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clinical trials if it had a negative risk-benefit ratio [38,39]. So, the iso-
lated assessment of activity, safety, pharmacokinetics, or pharmacody-
namic data would have no sense. In order to combine these data in a 
single evaluation, it is important to grade qualitatively the intensity of 
clinical activity. Thus, analyzing both NI and superiority objectives is 
more informative than only consider one of them separately [40,41]. 
4. Discussion 
Single-arm phase II trials are considered the first efficacy screenings 
of new investigational agents in humans. Additionally, these trials are 
important milestones towards testing safety and adapting the biomarker 
strategies validated in preclinical stages [34]. Although the NI question 
can be relevant in the phase II setting [5], it is not usually considered on 
designing single-arm clinical trials during early clinical development 
[42,43]. Previous forays into precision medicine have shown that 
identifying correctly both the target population and potential predictive 
biomarkers may be more critical for treatment success than simple 
demonstration of superior efficacy against an alternative [36,37,44]. 
The use of biomarker information in clinical trials has great potential for 
efficiently identifying patients most helped by specific treatments [45, 
46]. These biomarkers must have proven their clinical validity in pro-
spective, randomized trials with a superiority design in the enriched 
population [47]. Consequently, designing a proof-of-concept phase II 
study that permits NI and superiority analyses will allow for more 
informed decisions that rank the magnitude of clinical activity and other 
parameters, such as safety, pharmacokinetic, and pharmacodynamic 
data [7]. As NI analysis is allowed, it could be assumed that this design 
facilitates that ineffective therapies were evaluated in a randomized 
study. However, this only could be true if we evaluated the treatment 
exclusively based on the NI result, forgetting the other objectives. This 
makes no sense, because any new drug development plan performs a 
risk-benefit assessment weighing all the endpoints [38]. In accordance, a 
new therapy non-inferior to the standard of care with the same safety 
profile, and biological target will not be much promising. On the con-
trary, a new therapy with a good safety profile, that demonstrates to be 
non-inferior to the standard of care would be a promising companion if 
it targets a different biological pathway compared with the standard 
therapy [48]. 
Previous studies have proposed different strategies to evaluate 
multiple endpoints (efficacy and toxicity) in phase I and II single arm 
trials. EFFTox, Gumbel model, or continual reassessment method ad-
aptations for Bayesian perspective, or single-stage binomial trials and 
Simon two-stage adaptations for frequentist paradigm. However, these 
designs have been planned to evaluate the superiority of the new drug 
activity among a theorical or historical reference. They not considered to 
compare non-inferiority and superiority hypothesis to grade the 
magnitude of clinical activity in the early clinical stages [49–52]. 
A prior systematic review, which aimed to evaluate the character-
istics of phase II trials that best predict for phase III outcome, selected 
270 single-arm phase II studies between 1981 and 2012. All these 
selected studies led to a phase III clinical trial. The meta-analysis showed 
that 168 single-arm trials were not positive, while 61 (36.3%) achieved a 
positive phase III results despite not having obtained a positive result in 
the proof-of-concept study [36]. Additionally, Jardin DL and colleagues 
reported that 10% of FDA anti-cancer drugs approvals between January 
2009 and June 2014 obtained a negative result in prior phase II clinical 
trials [53]. In a number of these studies, despite the low response rates, 
clinical activity was considered not worse than conventional treatments 
and allowing to continue with Phase III trials according to other pa-
rameters, such as the prolonged duration of clinical benefit or the pos-
itive safety profile [25,29–31]. Overall, these data demonstrate that 
combining the superiority and NI analyses is useful to rank the intensity 
of clinical activity with other relevant parameters. This strategy of 
analysis of phase II trials has enriched the design of successful phase III 
leading to the marketing authorization of the product from regulatory 
authorities [53]. This suggests that the NI question is relevant in the 
phase II setting and it is not so rare. However, the NI hypothesis was not 
planned, and it was only considered to deal with negative findings in 
proof-of-concept trials. This strategy leads to an increase in the proba-
bility of type I error and the number of false positives [6]. In accordance, 
both systematic reviews reported and high rate of negative phase III 
trials after a negative phase II superiority trial (between 64% and 85%) 
[36,53]. However, if the decision to include a NI analysis had been 
preplanned and included in the statistical design, investigators would 
have additional information about magnitude of response (non-inferior 
or superior) or other parameters without a type I error inflation. In 
addition, the NI comparison with an historical control has probed its 
validity identifying subgroups of patients in adjuvant setting who can 
avoid the toxic effects of chemotherapy [26]. 
The most popular design for phase II cancer clinical trials is a single- 
arm, two-stage Simon’s design. Numerous extensions have been pro-
posed for the Simon’s design, including randomized multi-arm trials 
designed to select the winner among the proposed therapeutics (Pick- 
the-winner study design) [54]. However, the inference procedures used 
in two-stage designs are often not corrected to account for the adaptive 
nature of these designs. A maximum likelihood estimator of the RR, the 
number of positive responses/total number of patients, is biased. CI and 
p-value should not be computed as if the data were obtained in a single 
stage due to the possibility of early termination [10]. Different methods 
have been proposed to obtain a proper inference from the Simon’s 
two-stage design [10]. The use of the UMVUE to estimate RR is rec-
ommended as it addresses situations when the actual number of patients 
recruited is equal to or different from preplanned values [27]. The 
calculation of RR, p-values and CIs has been incorporated in open-access 
statistical libraries (packages “clinfun” and “OneArmPhaseTwoStudy”, 
R statistical software) based on previously published methods [11,28]. 
We observed some differences between calculated (p-value) and 
simulated values (type I error). However, they were not relevant to the 
most common design constraints used in phase II single-arm trials 
(0.01–0.1 type I errors and 0.1 to 0.2 type II errors). Using the UMVUE- 
based calculation method, we proved that the same level of agreement 
between calculated and simulated values (type I and II errors) results 
from both two-stage Simon’s superiority designs and designs in which NI 
analysis was allowed. Our findings suggest that the proposed method for 
analyzing NI in superiority-based designs did not introduce a bias under 
the most usual constrains for alpha and beta errors. So, our results 
recommend that single-arm study designs can be planned to attain the 
usual levels of statistical error (alpha and beta errors equal or lower than 
0.2). In study designs with error rates which are higher than usual levels, 
it would be necessary to simulate alpha and beta errors to confirm that 
statistical errors are attained at desired level. 
The major limitations of this method are based on bringing together 
the inherent complexities of a study with historical controls and a NI 
analysis. However, these limitations are quite common in comparative 
study designs of NI, because NIM must be established based on historical 
controls evidence [6]. Additionally, some bias (e.g. as selection of 
inappropriate patients, poor compliance and insufficient follow-up, that 
can lead to erroneously conclude that a treatment is not inferior to 
placebo in a comparative study) go against a positive achievement when 
the comparison is done among a theoretical rate of efficacy deduced 
from historical controls. As comparative designs of NI, to declare a 
therapy as non-inferior in a single-arm trial, we need to demonstrate 
assay sensitivity based on an adequate trial design and conduct [12]. In 
accordance, lower sample sizes in phase II single-arm trials are not more 
challenging for NI analyses respect to superiority ones if trial is properly 
preplanned and conducted. Our results suggest that we can conserve the 
same levels of alpha and beta errors after including the NI analysis 
without increase sample size. 
Furthermore, the NI analysis with the UMVUE-based calculation 
method may be extended to two-stage designs with both futility and 
superiority boundaries (as outlined in the Supplementary Methods) 
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[55]. We limited our results to two-stage designs that are most popularly 
for phase II cancer clinical trials, but the methods discussed in this 
article could be extended to phase II trials with any number of stages [9]. 
Likewise, we can design a single-arm time-to-event study with a NI 
hypothesis based on the exponential maximum likelihood estimator, 
one-sample log-rank tests or other approximations to the Kaplan-Meyer 
estimations [55–57]. If we assume the same number of patients as in 
superiority analysis, we would formulate the NI rejection hazard rate 
(λ0ni) from the hazard rate assumed under H0 in the superiority analysis 
(λ0) and the NIM estimated from historical studies [6] (λ0NI = λ0/NIM). 
Including a NI analysis in superiority-based clinical trials, may be 
useful for weighing additional factors such as clinical benefit duration, 
safety, cost, or biomarker strategy while assessing activity and early 
efficacy rate. The results of previous single-arm designs leading to a 
successful phase III trials or identifying subgroups of patients who can 
avoid the toxic effects of chemotherapy suggest that NI question is 
relevant in non-comparative studies. Implementation of this strategy can 
be achieved through simple adaptations to the Simon’s two-stage design 
and other existing designs for one-arm phase II clinical trials. 
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Denès, C. Falandry, C. Fournel-Fédérico, G. Freyer, S. Tartas, V. Trillet-Lenoir, 
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